摘要
目的研究甲泼尼龙联合艾拉莫德治疗原发性干燥综合征疗效及对免疫球蛋白水平的影响。方法选择该院收治的46例原发性干燥综合征患者作为研究对象,所有患者的病例选取时间均在2018年4月—2019年9月,患者通过药物进行临床治疗,并且根据两种不同的药物治疗方式随机将患者分成观察组和对照组,其中对照组采用甲泼尼龙和硫酸羟氯喹治疗,观察组在此基础上联合艾拉莫德治疗,对比分析两组患者的治疗效果、治疗前后预后指标、不良反应发生率以及治疗前后的血清指标情况。结果观察组的治疗效果为91.3%,高于对照组的56.52%(χ2=7.216,P=0.007)。观察组在唾液流速率、报告指数评分等治疗前后预后指标情况分别为(0.52±0.14)分、(1.57±0.42)分、(7.23±1.01)分、(2.73±0.72)分,均要优于对照组(0.51±0.13)分、(1.02±0.24)分、(7.34±1.02)分、(5.21±0.87)分(t=0.251、5.453、0.368、10.532,P<0.05)。观察组在胃肠道不适、肝功能异常、皮疹等不良反应发生率为13.04%,低于对照组的43.48%(χ2=5.254,P=0.022)。观察组在治疗前后的IgG、ESR等血清指标情况分别为(23.47±2.68)mg/L、(13.25±1.02)mg/L、(53.22±11.35)mm/h、(16.35±6.54)mm/h,均要优于对照组(23.97±2.71)mg/L、(16.56±1.45)mg/L、(54.37±11.41)mm/h、(22.67±8.26)mm/h(t=0.629、8.954、0.343、2.877),治疗后的P<0.05。结论甲泼尼龙联合艾拉莫德治疗原发性干燥综合征疗效及对免疫球蛋白水平的影响效果显著,能够有效促进患者临床疾病的治疗。
Objective To study the effect of methylprednisolone combined with ilamod on the treatment of primary Sjogren’s syndrome and its effect on immunoglobulin levels.Methods Forty-six patients with primary Sjogren’s syndrome treated in the hospital were selected as the research objects.All patients were selected from April 2018 to September 2019.The patients were treated clinically with drugs,and according to two Patients were randomly divided into observation group and control group by different drug treatment methods.The control group was treated with methylprednisolone and hydroxychloroquine sulfate,and the observation group was combined with ilammod treatment on this basis.The treatment effects of the two groups of patients were compared and analyzed,as well as the prognostic indicators before and after treatment,incidence of adverse reactions,and serum indicators before and after treatment.Results The treatment effect of the observation group was 91.3%,which was higher than 56.52% of the control group(χ2=7.216,P=0.007).The prognostic indicators of the observation group before and after treatment such as saliva flow rate and report index score were(0.52±0.14)points,(1.57±0.42)points,(7.23±1.01)points,(2.73±0.72)points,better than the control group(0.51±0.13)points,(1.02±0.24)points,(7.34±1.02)points,(5.21±0.87)points(t=0.251,5.453,0.368,10.532,P<0.05).The incidence of adverse reactions such as gastrointestinal discomfort,liver dysfunction,and rash in the observation group was 13.04%,which was lower than 43.48% in the control group(χ2=5.254,P=0.022).The serum indicators of IgG and ESR in the observation group before and after treatment were(23.47±2.68)mg/L,(13.25±1.02)mg/L,(53.22±11.35)mm/h,(16.35±6.54)mm/h,which were better than those in the control group(23.97±2.71)mg/L,(16.56±1.45)mg/L,(54.37±11.41)mm/h,(22.67±8.26)mm/h(t=0.629,8.954,0.343,2.877,after treatment P<0.05).Conclusion Methylprednisolone combined with iramod for the treatment of primary Sjogren’s syndrome and its effect on immunoglobulin levels are significant,which can effectively promote the treatment of clinical diseases in patients.
作者
李蓉蓉
龙红
LI Rong-rong;LONG Hong(Department of Rheumatology and Immunology,Yunnan Diannan Central Hospital(Honghe First People's Hospital),Honghe,Yunnan Province,661199 China)
出处
《世界复合医学》
2020年第5期189-191,共3页
World Journal of Complex Medicine
